Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.72 |
| ▸ | USP2 | O75604 | 6/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | NAMPT | P43490 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148047 | 0.94 | HPGDS (0.75) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148048 | 0.91 | HPGDS (0.74) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL3076704 | 0.91 | HPGDS (0.74) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148282 | 0.90 | HPGDS (0.73) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL3075272 | 0.90 | HPGDS (0.65) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148237 | 0.88 | HPGDS (0.64) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148124 | 0.88 | HPGDS (0.64) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148276 | 0.88 | HPGDS (0.70) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148228 | 0.87 | SMN1; SMN2 (0.73) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 | |
| SCHEMBL13148287 | 0.87 | HPGDS (0.69) | HPGDSCYP3A4USP2CYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | HPGDS 1/4885CYP3A4 2577/4885USP2 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.